将 STING 激动剂用于癌症免疫疗法

IF 7.1 2区工程技术 Q1 BIOCHEMICAL RESEARCH METHODS

Current opinion in biotechnology Pub Date : 2024-03-10 DOI:10.1016/j.copbio.2024.103105

Jianping Wang , Fanfei Meng , Yoon Yeo

{"title":"将 STING 激动剂用于癌症免疫疗法","authors":"Jianping Wang , Fanfei Meng , Yoon Yeo","doi":"10.1016/j.copbio.2024.103105","DOIUrl":null,"url":null,"abstract":"<div><p>Agonists of the cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS)-Stimulator of Interferon Genes (STING) pathway, a critical mediator of innate immune response to foreign invaders with DNA, have gained significant interest in cancer immunotherapy. STING agonists are envisioned as a way of complementing the antitumor activity of the patient’s immune system and immune checkpoint blockade therapy. However, their clinical development has been challenging due to the poor pharmacokinetic and physicochemical properties. This review discusses drug delivery efforts to circumvent the challenges, their accomplishment, and unmet needs based on the last five years of literature.</p></div>","PeriodicalId":10833,"journal":{"name":"Current opinion in biotechnology","volume":"87 ","pages":"Article 103105"},"PeriodicalIF":7.1000,"publicationDate":"2024-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Delivery of STING agonists for cancer immunotherapy\",\"authors\":\"Jianping Wang , Fanfei Meng , Yoon Yeo\",\"doi\":\"10.1016/j.copbio.2024.103105\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Agonists of the cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS)-Stimulator of Interferon Genes (STING) pathway, a critical mediator of innate immune response to foreign invaders with DNA, have gained significant interest in cancer immunotherapy. STING agonists are envisioned as a way of complementing the antitumor activity of the patient’s immune system and immune checkpoint blockade therapy. However, their clinical development has been challenging due to the poor pharmacokinetic and physicochemical properties. This review discusses drug delivery efforts to circumvent the challenges, their accomplishment, and unmet needs based on the last five years of literature.</p></div>\",\"PeriodicalId\":10833,\"journal\":{\"name\":\"Current opinion in biotechnology\",\"volume\":\"87 \",\"pages\":\"Article 103105\"},\"PeriodicalIF\":7.1000,\"publicationDate\":\"2024-03-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current opinion in biotechnology\",\"FirstCategoryId\":\"5\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0958166924000417\",\"RegionNum\":2,\"RegionCategory\":\"工程技术\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMICAL RESEARCH METHODS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current opinion in biotechnology","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0958166924000417","RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

摘要

环鸟苷单磷酸-腺苷单磷酸合成酶（cGAS）-干扰素基因刺激器（STING）通路是先天免疫对外来入侵者 DNA 作出反应的关键介质，其激动剂在癌症免疫疗法中备受关注。STING 激动剂被认为是对患者免疫系统抗肿瘤活性和免疫检查点阻断疗法的一种补充。然而，由于药代动力学和理化特性较差，其临床开发一直面临挑战。本综述根据过去五年的文献，讨论了为规避这些挑战所做的给药努力、所取得的成就以及尚未满足的需求。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Delivery of STING agonists for cancer immunotherapy

Agonists of the cyclic guanosine monophosphate–adenosine monophosphate synthase (cGAS)-Stimulator of Interferon Genes (STING) pathway, a critical mediator of innate immune response to foreign invaders with DNA, have gained significant interest in cancer immunotherapy. STING agonists are envisioned as a way of complementing the antitumor activity of the patient’s immune system and immune checkpoint blockade therapy. However, their clinical development has been challenging due to the poor pharmacokinetic and physicochemical properties. This review discusses drug delivery efforts to circumvent the challenges, their accomplishment, and unmet needs based on the last five years of literature.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Current opinion in biotechnology 工程技术-生化研究方法

CiteScore

16.20

自引率

2.60%

发文量

226

审稿时长

4-8 weeks

期刊介绍： Current Opinion in Biotechnology (COBIOT) is renowned for publishing authoritative, comprehensive, and systematic reviews. By offering clear and readable syntheses of current advances in biotechnology, COBIOT assists specialists in staying updated on the latest developments in the field. Expert authors annotate the most noteworthy papers from the vast array of information available today, providing readers with valuable insights and saving them time. As part of the Current Opinion and Research (CO+RE) suite of journals, COBIOT is accompanied by the open-access primary research journal, Current Research in Biotechnology (CRBIOT). Leveraging the editorial excellence, high impact, and global reach of the Current Opinion legacy, CO+RE journals ensure they are widely read resources integral to scientists' workflows. COBIOT is organized into themed sections, each reviewed once a year. These themes cover various areas of biotechnology, including analytical biotechnology, plant biotechnology, food biotechnology, energy biotechnology, environmental biotechnology, systems biology, nanobiotechnology, tissue, cell, and pathway engineering, chemical biotechnology, and pharmaceutical biotechnology.